Cardiol Therapeutics (TSE:CRDL) Posts Earnings Results

Cardiol Therapeutics (TSE:CRDL) posted its earnings results on Tuesday. The company reported C($0.07) earnings per share for the quarter, FiscalAI reports.

Cardiol Therapeutics Trading Up 10.5%

TSE:CRDL opened at C$1.89 on Wednesday. The company’s 50 day moving average is C$1.41 and its 200-day moving average is C$1.44. The company has a quick ratio of 6.84, a current ratio of 3.89 and a debt-to-equity ratio of 1.40. Cardiol Therapeutics has a 12 month low of C$1.09 and a 12 month high of C$2.17. The firm has a market cap of C$211.08 million, a price-to-earnings ratio of -4.61 and a beta of 0.94.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.